curasan AG

euro adhoc: curasan AG
curasan AG: New Products for Oral Surgery

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- New Products 12.03.2008 curasan AG (ISIN DE 000 549 453 8) listed in the Prime Standard signed a distributorship agreement with Osteogenics Biomedical Inc., Lubbock, Texas, USA. Thereby, curasan is granted the distribution rights for a powerful product package expected to be marketed throughout Europe under curasan´s own brand name as of summer of 2008. The package contains, among others, five membrane lines with different features, available in various sizes and shapes, suitable for specific indications. With this considerable product line extension in the field of dental surgery and implantology curasan provides known products of optimized quality as well as new solutions which ideally supplement the existing range. These products, the license for which was obtained without significant advance costs, will contribute substantially to the planned overproportional growth in sales. About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. With the REVOIS® implant system, the company's sales is focusing more prominently on the growth market of dental surgery/implantology. The majority of new products emerging from the substantial development pipeline are to be offered under licence within other medical fields. Please visit curasan's corporate website at end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: curasan AG Im Internet recherchierbar: Further inquiry note: Dr. Erwin Amashaufer, curasan AG, phone +49 6027 4686-465, email: Andrea Weidner, curasan AG, phone +49 6027 4686-467, email: Branche: Biotechnology ISIN: DE0005494538 WKN: 549453 Index: CDAX, Classic All Share, Prime All Share Börsen: Börse Frankfurt / regulated dealing/prime standard Börse Berlin / free trade Börse Hamburg / free trade Börse Stuttgart / free trade Börse Düsseldorf / free trade Börse Hannover / free trade Börse München / free trade

Das könnte Sie auch interessieren: